One giant reason to buy CSL Limited shares

Here's how CSL Limited (ASX:CSL) delivers market-beating return on equity…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Don't be fooled by last week's dip in share price as CSL Limited (ASX: CSL) reported its annual results. The company is in great shape.

Cash flow from operating activities was up a solid 6%, the company continued to invest in R&D and over US$1.2 billion in cash was returned to investors through dividends and share buy-backs.

Returns on equity holding strong

But one of the features I like most about CSL is its huge return on equity (ROE), which completely blows away the 10% average for U.S. healthcare product companies. Let's take a look and see how it held up in the 2016 financial year:

CSL Limited 2016 2015 2014 2013 2012
Net Income (US$) 1,242 1,379 1,307 1,211 1,024
Total equity (US$) 2,567 2,746 3,162 3,018 3,477
ROE 48% 50% 41% 40% 29%

 

It's interesting to see that although ROE held strong over the last 12 months, both net income and total equity dropped.

Net income dropped mostly because the company was investing more cash into its new Seqirus Influenza business. Meanwhile equity dropped as the company took on more debt to fund the acquisition. Both points show that CSL is continuing to reinvest for long-term growth which is good news.

Why does CSL use debt, rather than fund the growth from its strong cash flows? With borrowing costs so low it makes sense to use debt to fund moderate growth if the company knows it can generate new income to pay it back.

Breaking down return on equity

To see where CSL's huge 48% ROE comes from, we can break it out into three components using the DuPont analysis:

  1. Net profit margin (Net Income ÷ Revenue) 0.21
  2. Asset Turnover (Revenue ÷ Assets) 0.78
  3. Equity Multiplier (Assets ÷ Shareholders' Equity) 2.95

Return on equity = (0.21) x (0.78) x (2.95) = 48.32%

Even by healthcare standards CSL's 48% ROE is insane, with only Cochlear Limited (ASX: COH) coming close. But when we break it down we can see that the big driver of the returns is CSL's use of debt to fund assets; the high equity multiplier. Without this, if CSL didn't leverage its assets with borrowed money, ROE would only be 16.38%.

That's not to say the company is over leveraged, especially when CSL has strong cash flows to service the interest, but if a comparable investment had a higher unleveraged return, we may prefer to buy it.

Foolish takeaway

To me, CSL is to healthcare what Johnson & Johnson is to consumer products, or what Nestlé is to snack foods; a well-structured staple producer with low cyclical volatility and strong margins and volumes.

It's a company I would love to own, and I will certainly be watching for any further weakness in share price.

Motley Fool contributor Regan Pearson has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »